HRP20010052A2 - Heterocyclic compounds as inhibitors of rotamase enzymes - Google Patents
Heterocyclic compounds as inhibitors of rotamase enzymes Download PDFInfo
- Publication number
- HRP20010052A2 HRP20010052A2 HR20010052A HRP20010052A HRP20010052A2 HR P20010052 A2 HRP20010052 A2 HR P20010052A2 HR 20010052 A HR20010052 A HR 20010052A HR P20010052 A HRP20010052 A HR P20010052A HR P20010052 A2 HRP20010052 A2 HR P20010052A2
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- alkyl
- formula
- benzoxazol
- piperidinecarboxamide
- Prior art date
Links
- 101710147152 Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 title description 6
- 102000004190 Enzymes Human genes 0.000 title description 5
- 108090000790 Enzymes Proteins 0.000 title description 5
- 239000003112 inhibitor Substances 0.000 title description 4
- 101710103508 FK506-binding protein Proteins 0.000 title description 2
- 101710104425 FK506-binding protein 2 Proteins 0.000 title description 2
- 101710104423 FK506-binding protein 3 Proteins 0.000 title description 2
- 101710104333 FK506-binding protein 4 Proteins 0.000 title description 2
- 101710104342 FK506-binding protein 5 Proteins 0.000 title description 2
- 101710149710 FKBP-type 16 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710121306 FKBP-type 22 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710180800 FKBP-type peptidyl-prolyl cis-trans isomerase FkpA Proteins 0.000 title description 2
- 101710104030 Long-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710114693 Outer membrane protein MIP Proteins 0.000 title description 2
- 101710116692 Peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710111764 Peptidyl-prolyl cis-trans isomerase FKBP10 Proteins 0.000 title description 2
- 101710111749 Peptidyl-prolyl cis-trans isomerase FKBP11 Proteins 0.000 title description 2
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 title description 2
- 101710111757 Peptidyl-prolyl cis-trans isomerase FKBP14 Proteins 0.000 title description 2
- 101710111682 Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 title description 2
- 101710111689 Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 title description 2
- 101710147154 Peptidyl-prolyl cis-trans isomerase FKBP2 Proteins 0.000 title description 2
- 101710147149 Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 title description 2
- 101710147150 Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 title description 2
- 101710147138 Peptidyl-prolyl cis-trans isomerase FKBP7 Proteins 0.000 title description 2
- 101710147137 Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 title description 2
- 101710147136 Peptidyl-prolyl cis-trans isomerase FKBP9 Proteins 0.000 title description 2
- 101710174853 Peptidyl-prolyl cis-trans isomerase Mip Proteins 0.000 title description 2
- 101710200991 Peptidyl-prolyl cis-trans isomerase, rhodopsin-specific isozyme Proteins 0.000 title description 2
- 101710092145 Peptidyl-prolyl cis-trans isomerase-like 1 Proteins 0.000 title description 2
- 101710092146 Peptidyl-prolyl cis-trans isomerase-like 2 Proteins 0.000 title description 2
- 101710092148 Peptidyl-prolyl cis-trans isomerase-like 3 Proteins 0.000 title description 2
- 101710092149 Peptidyl-prolyl cis-trans isomerase-like 4 Proteins 0.000 title description 2
- 101710113444 Probable parvulin-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710090737 Probable peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710133309 Putative peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 101710124237 Short-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 title description 2
- 102100038809 Peptidyl-prolyl cis-trans isomerase FKBP9 Human genes 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 216
- -1 -CONR5R6 Chemical group 0.000 claims description 132
- 238000002360 preparation method Methods 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 75
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 46
- 208000012902 Nervous system disease Diseases 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 239000012453 solvate Substances 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 208000024827 Alzheimer disease Diseases 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 210000003169 central nervous system Anatomy 0.000 claims description 23
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 23
- 208000025966 Neurological disease Diseases 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 208000018737 Parkinson disease Diseases 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 12
- 208000016621 Hearing disease Diseases 0.000 claims description 12
- 208000026072 Motor neurone disease Diseases 0.000 claims description 12
- 206010039966 Senile dementia Diseases 0.000 claims description 12
- 208000009205 Tinnitus Diseases 0.000 claims description 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 208000005264 motor neuron disease Diseases 0.000 claims description 12
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 12
- 210000000278 spinal cord Anatomy 0.000 claims description 12
- 231100000886 tinnitus Toxicity 0.000 claims description 12
- 230000000472 traumatic effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000000750 progressive effect Effects 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 230000009689 neuronal regeneration Effects 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 206010003694 Atrophy Diseases 0.000 claims description 6
- 208000006373 Bell palsy Diseases 0.000 claims description 6
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 6
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims description 6
- 208000003435 Optic Neuritis Diseases 0.000 claims description 6
- 208000024777 Prion disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 6
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 6
- 201000011101 acute retrobulbar neuritis Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 230000037444 atrophy Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 210000000133 brain stem Anatomy 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 6
- 208000036319 cervical spondylosis Diseases 0.000 claims description 6
- 229960000860 dapsone Drugs 0.000 claims description 6
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 201000006938 muscular dystrophy Diseases 0.000 claims description 6
- 206010028417 myasthenia gravis Diseases 0.000 claims description 6
- 208000020469 nerve plexus disease Diseases 0.000 claims description 6
- 230000007514 neuronal growth Effects 0.000 claims description 6
- 208000020911 optic nerve disease Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 6
- 208000022670 retrobulbar neuritis Diseases 0.000 claims description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 6
- 208000005801 spondylosis Diseases 0.000 claims description 6
- 206010048627 thoracic outlet syndrome Diseases 0.000 claims description 6
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 6
- JRLIAYYZWGPBRQ-FPOVZHCZSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-benzylpyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1CC1=CC=CC=C1 JRLIAYYZWGPBRQ-FPOVZHCZSA-N 0.000 claims description 5
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 5
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- ZKIWJMXYIKXRBG-IAXKEJLGSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-(1-benzylpiperidin-3-yl)piperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)NC(C1)CCCN1CC1=CC=CC=C1 ZKIWJMXYIKXRBG-IAXKEJLGSA-N 0.000 claims description 3
- REMMGBMFSQXIFI-FPOVZHCZSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-[(3-carbamoylphenyl)methyl]pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(CN2C[C@H](CC2)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)=C1 REMMGBMFSQXIFI-FPOVZHCZSA-N 0.000 claims description 3
- DBLZXAKIKCKPNV-FPOVZHCZSA-N (2s)-n-[(3s)-1-benzylpyrrolidin-3-yl]-1-(6-bromo-1,3-benzoxazol-2-yl)piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@@H]2CCCCN2C2=NC3=CC=C(C=C3O2)Br)CN1CC1=CC=CC=C1 DBLZXAKIKCKPNV-FPOVZHCZSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 206010019909 Hernia Diseases 0.000 claims description 3
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 3
- 125000004599 benzpyrazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- BEWLHCCYDPQJQZ-RXVVDRJESA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(1h-indazole-6-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C1=CC=C2OC(N3CCCC[C@H]3C(N[C@@H]3CN(CC3)C(=O)C=3C=C4NN=CC4=CC=3)=O)=NC2=C1 BEWLHCCYDPQJQZ-RXVVDRJESA-N 0.000 claims description 2
- CZGPSEFYACAIBB-JTSKRJEESA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(2-chloroquinoline-4-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C1=CC=CC2=NC(Cl)=CC(C(=O)N3C[C@H](CC3)NC(=O)[C@H]3N(CCCC3)C=3OC4=CC=CC=C4N=3)=C21 CZGPSEFYACAIBB-JTSKRJEESA-N 0.000 claims description 2
- NELHIUTYUIMQDK-IADCTJSHSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(2-phenylquinoline-4-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1C(=O)C(C1=CC=CC=C1N=1)=CC=1C1=CC=CC=C1 NELHIUTYUIMQDK-IADCTJSHSA-N 0.000 claims description 2
- JVDOFPXYBFCQBY-JHOBJCJYSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(6-methoxy-2-phenylquinoline-4-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C1=C(C(=O)N2C[C@H](CC2)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)C2=CC(OC)=CC=C2N=C1C1=CC=CC=C1 JVDOFPXYBFCQBY-JHOBJCJYSA-N 0.000 claims description 2
- MOQWZJNJXNUCQS-CVDCTZTESA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(quinoline-2-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C1=CC=C2OC(N3CCCC[C@H]3C(N[C@@H]3CN(CC3)C(=O)C=3N=C4C=CC=CC4=CC=3)=O)=NC2=C1 MOQWZJNJXNUCQS-CVDCTZTESA-N 0.000 claims description 2
- 125000004227 1,3-benzoxazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)OC2=C1[H] 0.000 claims description 2
- 208000012287 Prolapse Diseases 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 230000000926 neurological effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- WAXKYKGKKYUWTA-CUNXSJBXSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(2-piperidin-1-ylquinoline-4-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1C(=O)C(C1=CC=CC=C1N=1)=CC=1N1CCCCC1 WAXKYKGKKYUWTA-CUNXSJBXSA-N 0.000 claims 1
- NXQLLSGAZNBSMS-MBSDFSHPSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(4-methoxyquinoline-2-carbonyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C1=CC=C2OC(N3CCCC[C@H]3C(=O)N[C@H]3CCN(C3)C(=O)C=3C=C(C4=CC=CC=C4N=3)OC)=NC2=C1 NXQLLSGAZNBSMS-MBSDFSHPSA-N 0.000 claims 1
- 238000007259 addition reaction Methods 0.000 claims 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000007257 deesterification reaction Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 86
- 239000002904 solvent Substances 0.000 description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 53
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- 230000002829 reductive effect Effects 0.000 description 42
- 239000012043 crude product Substances 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 26
- 239000007787 solid Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 235000019341 magnesium sulphate Nutrition 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 14
- 235000011114 ammonium hydroxide Nutrition 0.000 description 14
- WXTUPZCUXANAJB-JTQLQIEISA-N (2s)-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C1=NC2=CC=CC=C2O1 WXTUPZCUXANAJB-JTQLQIEISA-N 0.000 description 13
- 125000001475 halogen functional group Chemical group 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- MZCSZOLSCYJVOU-JSGCOSHPSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)N[C@H]1CCNC1 MZCSZOLSCYJVOU-JSGCOSHPSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 230000000508 neurotrophic effect Effects 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 7
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229940053128 nerve growth factor Drugs 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000014511 neuron projection development Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000000609 ganglia Anatomy 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- JZRNLLJLJVZCMG-HNNXBMFYSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-piperidin-4-ylpiperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)NC1CCNCC1 JZRNLLJLJVZCMG-HNNXBMFYSA-N 0.000 description 4
- HBVNLKQGRZPGRP-NSHDSACASA-N (3s)-1-benzylpyrrolidin-3-amine Chemical compound C1[C@@H](N)CCN1CC1=CC=CC=C1 HBVNLKQGRZPGRP-NSHDSACASA-N 0.000 description 4
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- CWFCFEKUVPYMAB-NSHDSACASA-N methyl (2s)-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCCN1C1=NC2=CC=CC=C2O1 CWFCFEKUVPYMAB-NSHDSACASA-N 0.000 description 4
- 230000007971 neurological deficit Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WVQBCPKMRCVDJD-JTQLQIEISA-N (2s)-1-(1,3-benzothiazol-2-yl)piperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C1=NC2=CC=CC=C2S1 WVQBCPKMRCVDJD-JTQLQIEISA-N 0.000 description 3
- JRLIAYYZWGPBRQ-CTNGQTDRSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3r)-1-benzylpyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1CC1=CC=CC=C1 JRLIAYYZWGPBRQ-CTNGQTDRSA-N 0.000 description 3
- WSKQFWTWMRABMA-ICSRJNTNSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1CC1=CC=CC=N1 WSKQFWTWMRABMA-ICSRJNTNSA-N 0.000 description 3
- RUUSDMCJGKRDQR-JTQLQIEISA-N (2s)-1-(6-bromo-1,3-benzoxazol-2-yl)piperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C1=NC2=CC=C(Br)C=C2O1 RUUSDMCJGKRDQR-JTQLQIEISA-N 0.000 description 3
- GSYYAQYEJQVYOY-JTQLQIEISA-N (2s)-1-(6-chloro-1,3-benzothiazol-2-yl)piperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C1=NC2=CC=C(Cl)C=C2S1 GSYYAQYEJQVYOY-JTQLQIEISA-N 0.000 description 3
- RFQYLUMBICIDTD-AWEZNQCLSA-N (2s)-1-[1-[(2-methylpropan-2-yl)oxycarbonyl]benzimidazol-2-yl]piperidine-2-carboxylic acid Chemical compound N=1C2=CC=CC=C2N(C(=O)OC(C)(C)C)C=1N1CCCC[C@H]1C(O)=O RFQYLUMBICIDTD-AWEZNQCLSA-N 0.000 description 3
- DVAGURFSEKIHOR-VWLOTQADSA-N (2s)-n-(1-benzhydrylazetidin-3-yl)-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)NC(C1)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 DVAGURFSEKIHOR-VWLOTQADSA-N 0.000 description 3
- AQUMROUGWVRZLQ-LLVKDONJSA-N (3r)-1-(pyridin-2-ylmethyl)piperidin-3-ol Chemical compound C1[C@H](O)CCCN1CC1=CC=CC=N1 AQUMROUGWVRZLQ-LLVKDONJSA-N 0.000 description 3
- JKRPSGIDKAQDJZ-SNVBAGLBSA-N (3r)-1-[(2-fluoropyridin-4-yl)methyl]piperidin-3-ol Chemical compound C1[C@H](O)CCCN1CC1=CC=NC(F)=C1 JKRPSGIDKAQDJZ-SNVBAGLBSA-N 0.000 description 3
- IUKFZRSHRLIKHR-JKSUJKDBSA-N (3r,5s)-5-(phenoxymethyl)-1-(pyridin-4-ylmethyl)pyrrolidin-3-ol Chemical compound C([C@@H]1C[C@H](CN1CC=1C=CN=CC=1)O)OC1=CC=CC=C1 IUKFZRSHRLIKHR-JKSUJKDBSA-N 0.000 description 3
- WALASTUVCKWKCP-VHSXEESVSA-N (3r,5s)-5-(phenoxymethyl)pyrrolidin-3-ol Chemical compound C1[C@@H](O)CN[C@@H]1COC1=CC=CC=C1 WALASTUVCKWKCP-VHSXEESVSA-N 0.000 description 3
- IILGAEIUCGHFMZ-JTQLQIEISA-N (3s)-1-(pyridin-3-ylmethyl)pyrrolidin-3-amine Chemical compound C1[C@@H](N)CCN1CC1=CC=CN=C1 IILGAEIUCGHFMZ-JTQLQIEISA-N 0.000 description 3
- LNXWMVGWXUTQOB-UHFFFAOYSA-N 1,3,4,1 2a-tetrahydropyrido[1',2':3,4]imidazo[1,2-a][1,3]benzimidazol-12(2h)-one Chemical compound C12=NC3=CC=CC=C3N2C(=O)C2N1CCCC2 LNXWMVGWXUTQOB-UHFFFAOYSA-N 0.000 description 3
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010016648 Immunophilins Proteins 0.000 description 3
- 102000000521 Immunophilins Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- OKFKATYOUBCFPW-DLBZAZTESA-N benzyl (2s,4r)-4-hydroxy-2-(phenoxymethyl)pyrrolidine-1-carboxylate Chemical compound C([C@@H]1C[C@H](CN1C(=O)OCC=1C=CC=CC=1)O)OC1=CC=CC=C1 OKFKATYOUBCFPW-DLBZAZTESA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- SQGHBOAQFRJSBD-CABCVRRESA-N diazonio-[(3r,5s)-1-[(2-methylpropan-2-yl)oxycarbonyl]-5-(phenylmethoxymethyl)pyrrolidin-3-yl]azanide Chemical compound CC(C)(C)OC(=O)N1C[C@H](N=[N+]=[N-])C[C@H]1COCC1=CC=CC=C1 SQGHBOAQFRJSBD-CABCVRRESA-N 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- DXSGYVFSLRMGNM-LBPRGKRZSA-N ethyl (2s)-1-(1,3-benzothiazol-2-yl)piperidine-2-carboxylate Chemical compound CCOC(=O)[C@@H]1CCCCN1C1=NC2=CC=CC=C2S1 DXSGYVFSLRMGNM-LBPRGKRZSA-N 0.000 description 3
- DAOHYNCMMIRAGH-LBPRGKRZSA-N ethyl (2s)-1-(6-chloro-1,3-benzothiazol-2-yl)piperidine-2-carboxylate Chemical compound CCOC(=O)[C@@H]1CCCCN1C1=NC2=CC=C(Cl)C=C2S1 DAOHYNCMMIRAGH-LBPRGKRZSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- APCHKWZTSCBBJX-RGMNGODLSA-N methyl (2s)-piperidine-2-carboxylate;hydrochloride Chemical compound [Cl-].COC(=O)[C@@H]1CCCC[NH2+]1 APCHKWZTSCBBJX-RGMNGODLSA-N 0.000 description 3
- ODKLEQPZOCJQMT-UHFFFAOYSA-N n,n-diethylpyridin-4-amine Chemical compound CCN(CC)C1=CC=NC=C1 ODKLEQPZOCJQMT-UHFFFAOYSA-N 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 3
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- RSWMDUXINNEPAG-CUYJMHBOSA-N tert-butyl (2s,4r)-4-[[(2s)-1-(1,3-benzoxazol-2-yl)piperidine-2-carbonyl]amino]-2-(phenylmethoxymethyl)pyrrolidine-1-carboxylate Chemical compound C([C@@H]1C[C@H](CN1C(=O)OC(C)(C)C)NC(=O)[C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)OCC1=CC=CC=C1 RSWMDUXINNEPAG-CUYJMHBOSA-N 0.000 description 3
- NSJAQCIQJVLKBV-CABCVRRESA-N tert-butyl (2s,4r)-4-amino-2-(phenylmethoxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](N)C[C@H]1COCC1=CC=CC=C1 NSJAQCIQJVLKBV-CABCVRRESA-N 0.000 description 3
- NJEFYMIIQQPDJB-NRFANRHFSA-N tert-butyl 2-[(2s)-2-phenylmethoxycarbonylpiperidin-1-yl]benzimidazole-1-carboxylate Chemical compound O=C([C@@H]1CCCCN1C=1N(C2=CC=CC=C2N=1)C(=O)OC(C)(C)C)OCC1=CC=CC=C1 NJEFYMIIQQPDJB-NRFANRHFSA-N 0.000 description 3
- NSCSJISDXDCCGL-UHFFFAOYSA-N tert-butyl 2-chlorobenzimidazole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C(Cl)=NC2=C1 NSCSJISDXDCCGL-UHFFFAOYSA-N 0.000 description 3
- KDUYAPXDFKWBMN-SFHVURJKSA-N tert-butyl 4-[[(2s)-1-(1,3-benzoxazol-2-yl)piperidine-2-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC(=O)[C@H]1N(C=2OC3=CC=CC=C3N=2)CCCC1 KDUYAPXDFKWBMN-SFHVURJKSA-N 0.000 description 3
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MZCSZOLSCYJVOU-OCCSQVGLSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3r)-pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)N[C@@H]1CCNC1 MZCSZOLSCYJVOU-OCCSQVGLSA-N 0.000 description 2
- OSXMTXPLVDSAIS-WMZOPIPTSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-pyridin-2-ylpyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1C1=CC=CC=N1 OSXMTXPLVDSAIS-WMZOPIPTSA-N 0.000 description 2
- SDWZXHNHQNBKHB-NRFANRHFSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]piperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)NC(CC1)CCN1CC1=CC=NC=C1 SDWZXHNHQNBKHB-NRFANRHFSA-N 0.000 description 2
- UDFJJRKNDZXBNJ-ZFWWWQNUSA-N (2s)-n-[(3s)-1-(2-amino-2-oxoethyl)pyrrolidin-3-yl]-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxamide Chemical compound C1N(CC(=O)N)CC[C@@H]1NC(=O)[C@H]1N(C=2OC3=CC=CC=C3N=2)CCCC1 UDFJJRKNDZXBNJ-ZFWWWQNUSA-N 0.000 description 2
- UIPNINRODCWBJZ-HOCLYGCPSA-N (2s)-n-[(3s)-1-(3-amino-3-oxopropyl)pyrrolidin-3-yl]-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxamide Chemical compound C1N(CCC(=O)N)CC[C@@H]1NC(=O)[C@H]1N(C=2OC3=CC=CC=C3N=2)CCCC1 UIPNINRODCWBJZ-HOCLYGCPSA-N 0.000 description 2
- HBVNLKQGRZPGRP-LLVKDONJSA-N (3r)-1-benzylpyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1CC1=CC=CC=C1 HBVNLKQGRZPGRP-LLVKDONJSA-N 0.000 description 2
- VLECDMDGMKPUSK-NUBCRITNSA-N (3r)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCCNC1 VLECDMDGMKPUSK-NUBCRITNSA-N 0.000 description 2
- SOQFBVQBHKXECH-YDALLXLXSA-N (3s)-1-[(2-chloroquinolin-3-yl)methyl]pyrrolidin-3-amine;hydrochloride Chemical compound Cl.C1[C@@H](N)CCN1CC1=CC2=CC=CC=C2N=C1Cl SOQFBVQBHKXECH-YDALLXLXSA-N 0.000 description 2
- GAQLHBIVYBVXPF-YDNXMHBPSA-N 1-(1h-benzimidazol-2-yl)-n-[(3s)-1-benzylpyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C2N(CCCC2)C=2NC3=CC=CC=C3N=2)CN1CC1=CC=CC=C1 GAQLHBIVYBVXPF-YDNXMHBPSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 2
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SZIKRGHFZTYTIT-ZETCQYMHSA-N ethyl (2s)-piperidine-2-carboxylate Chemical compound CCOC(=O)[C@@H]1CCCCN1 SZIKRGHFZTYTIT-ZETCQYMHSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JHKJQWFHNIOUKY-UHFFFAOYSA-N iodomethylcyclopropane Chemical compound ICC1CC1 JHKJQWFHNIOUKY-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FSOMWDZZTOBGPC-NSHDSACASA-N methyl (2s)-1-(6-bromo-1,3-benzoxazol-2-yl)piperidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCCN1C1=NC2=CC=C(Br)C=C2O1 FSOMWDZZTOBGPC-NSHDSACASA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YTHWKVVGQNEBJL-SFTDATJTSA-N tert-butyl (2s,4s)-4-(4-methylphenyl)sulfonyloxy-2-(phenylmethoxymethyl)pyrrolidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@@H]1CN(C(=O)OC(C)(C)C)[C@H](COCC=2C=CC=CC=2)C1 YTHWKVVGQNEBJL-SFTDATJTSA-N 0.000 description 2
- RHHIPAUQALUPAC-ZDUSSCGKSA-N tert-butyl n-[(3s)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CCN1CC1=CC=CN=C1 RHHIPAUQALUPAC-ZDUSSCGKSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- UXBOHCIZDGKHIY-ICSRJNTNSA-N (2s)-1-(1,3-benzothiazol-2-yl)-n-[(3s)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2SC3=CC=CC=C3N=2)CN1CC1=CC=CN=C1 UXBOHCIZDGKHIY-ICSRJNTNSA-N 0.000 description 1
- JRVMDYUUCREPRG-QFIPXVFZSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-(1-benzylpiperidin-4-yl)piperidine-2-carboxamide Chemical compound O=C([C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)NC(CC1)CCN1CC1=CC=CC=C1 JRVMDYUUCREPRG-QFIPXVFZSA-N 0.000 description 1
- QQKVZQKLHLDEKU-HNNXBMFYSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-(1-ethylazetidin-3-yl)piperidine-2-carboxamide Chemical compound C1N(CC)CC1NC(=O)[C@H]1N(C=2OC3=CC=CC=C3N=2)CCCC1 QQKVZQKLHLDEKU-HNNXBMFYSA-N 0.000 description 1
- RGVWASLDUZGMEG-HOCLYGCPSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(1h-1,2,4-triazol-5-ylmethyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1CC=1N=CNN=1 RGVWASLDUZGMEG-HOCLYGCPSA-N 0.000 description 1
- NMQBVBCKIARRCO-ICSRJNTNSA-N (2s)-1-(1,3-benzoxazol-2-yl)-n-[(3s)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CN1CC1=CC=CN=C1 NMQBVBCKIARRCO-ICSRJNTNSA-N 0.000 description 1
- PZSSEOTUNXFLOH-RXVVDRJESA-N (2s)-n-[(3s)-1-[3-(2-amino-2-oxoethyl)phenyl]pyrrolidin-3-yl]-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxamide Chemical compound NC(=O)CC1=CC=CC(N2C[C@H](CC2)NC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)=C1 PZSSEOTUNXFLOH-RXVVDRJESA-N 0.000 description 1
- UKZPCQHWCFOOCJ-FPOVZHCZSA-N (2s)-n-[(3s)-1-benzylpyrrolidin-3-yl]-1-(6-chloro-1,3-benzothiazol-2-yl)piperidine-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)[C@@H]2CCCCN2C2=NC3=CC=C(C=C3S2)Cl)CN1CC1=CC=CC=C1 UKZPCQHWCFOOCJ-FPOVZHCZSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PIYNTNXOGGKWDR-UHFFFAOYSA-N 1-(2-chloroethyl)-2-methylimidazole Chemical compound CC1=NC=CN1CCCl PIYNTNXOGGKWDR-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LYTNNHXGUOKXFI-UHFFFAOYSA-N 1-benzhydrylazetidin-3-amine Chemical compound C1C(N)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 LYTNNHXGUOKXFI-UHFFFAOYSA-N 0.000 description 1
- HARWNWOLWMTQCC-UHFFFAOYSA-N 1-benzylpiperidin-3-amine Chemical compound C1C(N)CCCN1CC1=CC=CC=C1 HARWNWOLWMTQCC-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- NJQJGRGGIUNVAB-UHFFFAOYSA-N 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one Chemical compound BrC1=CC(Br)(Br)C=C(Br)C1=O NJQJGRGGIUNVAB-UHFFFAOYSA-N 0.000 description 1
- QDZGJGWDGLHVNK-UHFFFAOYSA-N 2,6-dichloro-1,3-benzothiazole Chemical compound C1=C(Cl)C=C2SC(Cl)=NC2=C1 QDZGJGWDGLHVNK-UHFFFAOYSA-N 0.000 description 1
- KFGBBVILFBMIOJ-UHFFFAOYSA-N 2-(1-ethylazetidin-3-yl)piperidine-2-carboxamide Chemical compound C1N(CC)CC1C1(C(N)=O)NCCCC1 KFGBBVILFBMIOJ-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- BBVQDWDBTWSGHQ-UHFFFAOYSA-N 2-chloro-1,3-benzoxazole Chemical compound C1=CC=C2OC(Cl)=NC2=C1 BBVQDWDBTWSGHQ-UHFFFAOYSA-N 0.000 description 1
- AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 1
- SDKQWXCBSNMYBN-UHFFFAOYSA-N 2-chloroquinoline-3-carbaldehyde Chemical compound C1=CC=C2C=C(C=O)C(Cl)=NC2=C1 SDKQWXCBSNMYBN-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- OOYATKQQGVPYQR-UHFFFAOYSA-N 3-(chloromethyl)benzamide Chemical compound NC(=O)C1=CC=CC(CCl)=C1 OOYATKQQGVPYQR-UHFFFAOYSA-N 0.000 description 1
- QVTCEZINLKFYJJ-UHFFFAOYSA-N 4-(bromomethyl)-2-fluoropyridine Chemical compound FC1=CC(CBr)=CC=N1 QVTCEZINLKFYJJ-UHFFFAOYSA-N 0.000 description 1
- WZIYCIBURCPKAR-UHFFFAOYSA-N 4-(chloromethyl)pyridine Chemical compound ClCC1=CC=NC=C1 WZIYCIBURCPKAR-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- GLAZMGQANOHRCR-UHFFFAOYSA-N 5-(chloromethyl)-1h-1,2,4-triazole Chemical compound ClCC1=NC=NN1 GLAZMGQANOHRCR-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- DBJRDZZHNXOLRS-RQBPZYBGSA-N Cl.C([C@@H](C1)OC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CCN1CC1=CC=CC=N1 Chemical compound Cl.C([C@@H](C1)OC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CCN1CC1=CC=CC=N1 DBJRDZZHNXOLRS-RQBPZYBGSA-N 0.000 description 1
- NRNGRDLZXZOFDD-DVWWASGRSA-N Cl.C([C@@H]1C[C@@H](CN1CC=1C=CN=CC=1)OC(=O)[C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)OC1=CC=CC=C1 Chemical compound Cl.C([C@@H]1C[C@@H](CN1CC=1C=CN=CC=1)OC(=O)[C@H]1N(CCCC1)C=1OC2=CC=CC=C2N=1)OC1=CC=CC=C1 NRNGRDLZXZOFDD-DVWWASGRSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 102000021523 FK506 binding proteins Human genes 0.000 description 1
- 108091011114 FK506 binding proteins Proteins 0.000 description 1
- 241001076388 Fimbria Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029301 Neurological disorders of the eye Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PQODJDRAIZUTJL-FPOVZHCZSA-N [(3s)-1-(pyridin-2-ylmethyl)piperidin-3-yl] (2s)-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxylate Chemical compound C([C@@H](C1)OC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)CCN1CC1=CC=CC=N1 PQODJDRAIZUTJL-FPOVZHCZSA-N 0.000 description 1
- XXNHQHUHBUDROG-ICSRJNTNSA-N [(3s)-1-[(2-fluoropyridin-4-yl)methyl]piperidin-3-yl] (2s)-1-(1,3-benzoxazol-2-yl)piperidine-2-carboxylate Chemical compound C1=NC(F)=CC(CN2C[C@H](CCC2)OC(=O)[C@H]2N(CCCC2)C=2OC3=CC=CC=C3N=2)=C1 XXNHQHUHBUDROG-ICSRJNTNSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- RSEPHCRIRACQML-LBPRGKRZSA-N benzyl (2s)-piperidine-2-carboxylate Chemical compound O=C([C@H]1NCCCC1)OCC1=CC=CC=C1 RSEPHCRIRACQML-LBPRGKRZSA-N 0.000 description 1
- WDEQGLDWZMIMJM-NWDGAFQWSA-N benzyl (2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound OC[C@@H]1C[C@@H](O)CN1C(=O)OCC1=CC=CC=C1 WDEQGLDWZMIMJM-NWDGAFQWSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- NTBUQDLWHOHUDR-UHFFFAOYSA-N ethyl acetate;n-ethylethanamine Chemical compound CCNCC.CCOC(C)=O NTBUQDLWHOHUDR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 230000007832 reinnervation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815880.1A GB9815880D0 (en) | 1998-07-21 | 1998-07-21 | Heterocycles |
| PCT/IB1999/001211 WO2000005232A1 (en) | 1998-07-21 | 1999-06-28 | Heterocyclic compounds as inhibitors of rotamase enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010052A2 true HRP20010052A2 (en) | 2001-12-31 |
Family
ID=10835920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010052A HRP20010052A2 (en) | 1998-07-21 | 2001-01-19 | Heterocyclic compounds as inhibitors of rotamase enzymes |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| HUP0200312A3 (en) | 1998-11-03 | 2002-12-28 | Basf Ag | Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use |
| DOP2000000107A (es) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| DE10124953A1 (de) * | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
| ES2383123T3 (es) * | 2004-06-29 | 2012-06-18 | Aventis Pharmaceuticals Inc. | Composición de unión a FKBP y su uso farmacéutico |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2006110683A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| ATE536349T1 (de) * | 2005-09-29 | 2011-12-15 | Abbott Lab | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
| ES2342007T3 (es) * | 2005-11-15 | 2010-06-30 | Abbott Laboratories | 1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp). |
| EP1976828B1 (en) | 2005-12-29 | 2016-12-21 | Celtaxsys, Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| KR101472248B1 (ko) | 2006-02-10 | 2014-12-16 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| RU2462458C2 (ru) * | 2006-02-10 | 2012-09-27 | Байомарин Ига Лимитед | Лечение миодистрофии дюшена |
| MX2008014004A (es) * | 2006-05-02 | 2008-11-12 | Abbott Lab | 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. |
| US8338455B2 (en) | 2006-12-20 | 2012-12-25 | Amgen Inc. | Compounds and methods of use |
| CL2008000666A1 (es) * | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro. |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| ES2617957T3 (es) * | 2007-08-03 | 2017-06-20 | Summit (Oxford) Limited | Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne |
| GB0715939D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| WO2010083199A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| GB0905664D0 (en) * | 2009-04-02 | 2009-05-13 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
| AU2014239585B2 (en) | 2013-03-14 | 2019-04-04 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
| MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| AU2014239567B2 (en) | 2013-03-14 | 2017-12-14 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
| AU2015264336B2 (en) * | 2014-05-19 | 2018-08-30 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds |
| JP7386815B2 (ja) | 2018-05-31 | 2023-11-27 | セルタクシー、エルエルシー | 呼吸器疾患患者の肺増悪を軽減する方法 |
| CN109111376B (zh) * | 2018-09-18 | 2021-09-14 | 四川医立特生物医药有限公司 | 一种2,5-双脱氧链霉胺衍生物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612332A (en) * | 1984-03-19 | 1997-03-18 | Alteon Inc. | Di- and triaminoguanidines, and methods of use |
| JPS6428245A (en) | 1987-07-22 | 1989-01-30 | Sumitomo Electric Industries | Production of fluoride glass |
| MX9202466A (es) | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
-
1998
- 1998-07-21 GB GBGB9815880.1A patent/GB9815880D0/en not_active Ceased
-
1999
- 1999-06-28 KR KR10-2004-7007852A patent/KR100468185B1/ko not_active IP Right Cessation
- 1999-06-28 SI SI9930246T patent/SI1100797T1/xx unknown
- 1999-06-28 CA CA002338214A patent/CA2338214C/en not_active Expired - Fee Related
- 1999-06-28 TR TR2001/00135T patent/TR200100135T2/xx unknown
- 1999-06-28 NZ NZ522270A patent/NZ522270A/en unknown
- 1999-06-28 AU AU42858/99A patent/AU765925B2/en not_active Ceased
- 1999-06-28 EA EA200100052A patent/EA003513B1/ru not_active IP Right Cessation
- 1999-06-28 JP JP2000561188A patent/JP3795329B2/ja not_active Expired - Fee Related
- 1999-06-28 DE DE69905582T patent/DE69905582T2/de not_active Expired - Fee Related
- 1999-06-28 HU HU0103413A patent/HUP0103413A3/hu unknown
- 1999-06-28 SK SK77-2001A patent/SK772001A3/sk unknown
- 1999-06-28 WO PCT/IB1999/001211 patent/WO2000005232A1/en not_active Application Discontinuation
- 1999-06-28 CN CNA2004100399747A patent/CN1611499A/zh active Pending
- 1999-06-28 OA OA1200100023A patent/OA11585A/en unknown
- 1999-06-28 AT AT99963123T patent/ATE233261T1/de not_active IP Right Cessation
- 1999-06-28 ID IDW20010155A patent/ID26991A/id unknown
- 1999-06-28 KR KR10-2001-7000927A patent/KR100450008B1/ko not_active IP Right Cessation
- 1999-06-28 AP APAP/P/2001/002046A patent/AP2001002046A0/en unknown
- 1999-06-28 NZ NZ508838A patent/NZ508838A/xx unknown
- 1999-06-28 CN CNA2003101239079A patent/CN1511837A/zh active Pending
- 1999-06-28 GE GEAP19995715A patent/GEP20033028B/en unknown
- 1999-06-28 DK DK99963123T patent/DK1100797T3/da active
- 1999-06-28 CN CNB998089974A patent/CN1174978C/zh not_active Expired - Fee Related
- 1999-06-28 EE EEP200100044A patent/EE200100044A/xx unknown
- 1999-06-28 ES ES99963123T patent/ES2191484T3/es not_active Expired - Lifetime
- 1999-06-28 BR BR9912330-4A patent/BR9912330A/pt not_active Application Discontinuation
- 1999-06-28 EP EP99963123A patent/EP1100797B1/en not_active Expired - Lifetime
- 1999-06-28 PL PL99345734A patent/PL345734A1/xx not_active Application Discontinuation
- 1999-06-28 IL IL14024499A patent/IL140244A0/xx unknown
- 1999-07-07 HN HN1999000106A patent/HN1999000106A/es unknown
- 1999-07-13 TW TW088111868A patent/TWI229672B/zh not_active IP Right Cessation
- 1999-07-19 AR ARP990103544A patent/AR019427A1/es unknown
- 1999-07-19 CO CO99045677A patent/CO5080782A1/es unknown
- 1999-07-20 PA PA19998478501A patent/PA8478501A1/es unknown
- 1999-07-20 DZ DZ990151A patent/DZ2851A1/xx active
- 1999-07-20 TN TNTNSN99147A patent/TNSN99147A1/fr unknown
- 1999-07-20 PE PE1999000727A patent/PE20001037A1/es not_active Application Discontinuation
- 1999-07-20 GT GT199900115A patent/GT199900115A/es unknown
- 1999-07-20 CR CR6073A patent/CR6073A/es not_active Application Discontinuation
- 1999-07-20 SV SV1999000102A patent/SV1999000102A/es not_active Application Discontinuation
- 1999-07-20 MA MA25691A patent/MA24936A1/fr unknown
- 1999-07-20 MY MYPI99003048A patent/MY118222A/en unknown
- 1999-07-21 US US09/358,107 patent/US6372736B1/en not_active Expired - Fee Related
-
2000
- 2000-12-22 IS IS5790A patent/IS5790A/is unknown
-
2001
- 2001-01-19 HR HR20010052A patent/HRP20010052A2/hr not_active Application Discontinuation
- 2001-01-19 NO NO20010322A patent/NO20010322L/no not_active Application Discontinuation
- 2001-02-14 BG BG105254A patent/BG105254A/xx unknown
-
2002
- 2002-01-23 US US10/056,901 patent/US6562964B1/en not_active Expired - Fee Related
- 2002-02-06 HK HK02100933.8A patent/HK1039779A1/zh unknown
-
2003
- 2003-04-09 JP JP2003105099A patent/JP2004002374A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6372736B1 (en) | Heterocyclic compounds as inhibitors of rotamase enzymes | |
| US5817677A (en) | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation | |
| EP0976732B1 (en) | 1,4-substituted cyclic amine derivatives | |
| US6225309B1 (en) | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | |
| EP2419413B1 (en) | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | |
| JP3668133B2 (ja) | ロータマーゼ酵素の阻害剤としての複素環式化合物 | |
| RU2332412C2 (ru) | Производные пиразола | |
| CA2873850C (en) | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | |
| JPH10503768A (ja) | アゼチジン、ピロリジンおよびピペリジン誘導体 | |
| US5973156A (en) | Piperidine and tetrahydropyridine derivatives | |
| JP3545341B2 (ja) | Ｆｋｂｐ阻害剤 | |
| US5998440A (en) | Azetidine, pyrrolidine and piperidine derivatives | |
| CZ2001236A3 (cs) | Heterocyklické sloučeniny jako inhibitory rotamasy | |
| MXPA98002988A (en) | Heterociclos of 5 members, cines containing these compounds, their use and processes to supreparate | |
| MXPA00008623A (es) | Compuestos heterociclicos como inhibidores de enzimas rotamasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040707 Year of fee payment: 6 |
|
| OBST | Application withdrawn |